Use of melanocortin-4 receptor agonist in prevention or treatment of rare genetic obesities

The present invention relates to the use of a compound of the following Formula 1 or a pharmaceutically acceptable salt thereof in the prevention or treatment of rare genetic obesities, specifically rare genetic obesity associated with proopiomelanocortin (POMC) deficiency: wherein R1 is C2-C5 alkyl...

Full description

Saved in:
Bibliographic Details
Main Authors PARK, HEE-DONG, HWANG, HYE-KYEONG, YEO, SU-JIN
Format Patent
LanguageChinese
English
Published 16.10.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to the use of a compound of the following Formula 1 or a pharmaceutically acceptable salt thereof in the prevention or treatment of rare genetic obesities, specifically rare genetic obesity associated with proopiomelanocortin (POMC) deficiency: wherein R1 is C2-C5 alkyl.
Bibliography:Application Number: TW202312104117